DrugBank: a comprehensive resource for in silico drug discovery and exploration
- PMID: 16381955
- PMCID: PMC1347430
- DOI: 10.1093/nar/gkj067
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Abstract
DrugBank is a unique bioinformatics/cheminformatics resource that combines detailed drug (i.e. chemical) data with comprehensive drug target (i.e. protein) information. The database contains >4100 drug entries including >800 FDA approved small molecule and biotech drugs as well as >3200 experimental drugs. Additionally, >14,000 protein or drug target sequences are linked to these drug entries. Each DrugCard entry contains >80 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data. Many data fields are hyperlinked to other databases (KEGG, PubChem, ChEBI, PDB, Swiss-Prot and GenBank) and a variety of structure viewing applets. The database is fully searchable supporting extensive text, sequence, chemical structure and relational query searches. Potential applications of DrugBank include in silico drug target discovery, drug design, drug docking or screening, drug metabolism prediction, drug interaction prediction and general pharmaceutical education. DrugBank is available at http://redpoll.pharmacy.ualberta.ca/drugbank/.
Figures
Similar articles
-
DrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. doi: 10.1093/nar/gkm958. Epub 2007 Nov 29. Nucleic Acids Res. 2008. PMID: 18048412 Free PMC article.
-
In silico drug exploration and discovery using DrugBank.Curr Protoc Bioinformatics. 2007 Jun;Chapter 14:Unit 14.4. doi: 10.1002/0471250953.bi1404s18. Curr Protoc Bioinformatics. 2007. PMID: 18428789
-
Using DrugBank for In Silico Drug Exploration and Discovery.Curr Protoc Bioinformatics. 2016 Jun 20;54:14.4.1-14.4.31. doi: 10.1002/cpbi.1. Curr Protoc Bioinformatics. 2016. PMID: 27322405
-
The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs.Expert Opin Ther Targets. 2011 Aug;15(8):903-12. doi: 10.1517/14728222.2011.586635. Epub 2011 May 28. Expert Opin Ther Targets. 2011. PMID: 21619487 Review.
-
Importance of molecular computer modeling in anticancer drug development.J BUON. 2007 Sep;12 Suppl 1:S101-18. J BUON. 2007. PMID: 17935268 Review.
Cited by
-
The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer.Comput Struct Biotechnol J. 2024 Oct 5;23:3634-3650. doi: 10.1016/j.csbj.2024.09.032. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 39469671 Free PMC article.
-
Transcriptome-wide Mendelian randomization during CD4+ T cell activation reveals immune-related drug targets for cardiometabolic diseases.Nat Commun. 2024 Oct 28;15(1):9302. doi: 10.1038/s41467-024-53621-7. Nat Commun. 2024. PMID: 39468075 Free PMC article.
-
Chemoproteogenomic stratification of the missense variant cysteinome.Nat Commun. 2024 Oct 28;15(1):9284. doi: 10.1038/s41467-024-53520-x. Nat Commun. 2024. PMID: 39468056 Free PMC article.
-
Knowledge graph driven medicine recommendation system using graph neural networks on longitudinal medical records.Sci Rep. 2024 Oct 26;14(1):25449. doi: 10.1038/s41598-024-75784-5. Sci Rep. 2024. PMID: 39455647 Free PMC article.
-
Empirically establishing drug exposure records directly from untargeted metabolomics data.bioRxiv [Preprint]. 2024 Oct 26:2024.10.07.617109. doi: 10.1101/2024.10.07.617109. bioRxiv. 2024. PMID: 39416075 Free PMC article. Preprint.
References
-
- Hatfield C.L., May S.K., Markoff J.S. Quality of consumer drug information provided by four web sites. Am. J. Health Syst. Pharm. 1999;56:2308–2311. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical